![](/img/cover-not-exists.png)
PCN43 COST COMPARISON OF ERLOTINIB VERSUS PEMETREXED FOR THE FIRST-LINE MAINTENANCE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER IN ITALY
S Ravera, S Walzer, J RayVolume:
13
Year:
2010
Language:
english
DOI:
10.1016/s1098-3015(11)71939-8
File:
PDF, 79 KB
english, 2010